Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 91

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 1
Chunk 91
---
416.3 Gross profit$171.5 $185.0 Gross profit %43.1 %44.4 %Operating income$37.4 $48.9 Operating income %9.4 %11.7 %

Net sales decreased $18.6 million, or 4.5%, due primarily to: 

•$21.5 million decrease, or 5.3%, due primarily to unfavorable impacts across multiple OTC businesses due to soft category consumption including lower net sales of $8.4 million in the Upper Respiratory category, as a result of lower incidence and consumption of cough cold products and timing of cough cold sell-in to customers compared to the prior year, as well as lower net sales of $4.8 million in the VMS category due primarily to deprioritization of nutraceuticals portfolio and lower net sales of $3.8 million from the Women's Health category due to supply constraints that have since been resolved, partially offset by new product sales of $6.8 million;

•$14.7 million decrease due to the prior year divestitures of the Hospital & Specialty Business and the Rare Diseases Business and the sale of branded products; partially offset by 

•$17.6 million increase from favorable foreign currency translation.

48

Perrigo Company plc - Item 2CSCI

CSCI net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)September 27, 2025September 28, 2024$ Change% ChangeSkin Care$91.7 $91.0 $0.7 0.8 %Upper Respiratory80.6 86.1 (5.6)(6.4)%Pain and Sleep-Aids56.3 56.9 (0.6)(1.1)%Healthy Lifestyle52.8 53.2 (0.3)(0.8)%VMS40.0 43.0 (3.0)(7.0)%Women's Health29.9 32.2 (2.4)(7.1)%Oral Care23.9 23.3 0.5 2.6 %Digestive Health10.6 9.0 1.6 17.8 %Other CSCI11.9 21.6 (9.6)(44.9)%Total CSCI$397.7